Unknown PHASE2 INTERVENTIONAL NCT00946374

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma (HD-MCL2003)

A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age < 55 Years With Primary Mantle-Cell-Lymphoma

Sponsor: Heidelberg University

Conditions Mantle-Cell Lymphoma

Interventions HLA-identical allogenic SCT High-dose BEAM plus autologous SCT Immunochemotherapy

Updated 5 times since 2017 Last updated: Jul 24, 2009 Started: Jul 31, 2004 Primary completion: Dec 31, 2010 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Mantle-Cell Lymphoma and is currently ongoing. Heidelberg University leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heidelberg University

Data source: Heidelberg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Heidelberg, Germany